Contrasting Presbia (OTCMKTS:LENSF) and IRIDEX (NASDAQ:IRIX)

IRIDEX (NASDAQ:IRIX) and Presbia (OTCMKTS:LENSF) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk.

Institutional and Insider Ownership

20.1% of IRIDEX shares are owned by institutional investors. 8.6% of IRIDEX shares are owned by company insiders. Comparatively, 74.2% of Presbia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for IRIDEX and Presbia, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IRIDEX	1	0	1	0	2.00
Presbia	0	0	0	0	0.00

IRIDEX currently has a consensus price target of $3.00, suggesting a potential upside of 264.03%. Given IRIDEX’s stronger consensus rating and higher possible upside, equities analysts plainly believe IRIDEX is more favorable than Presbia.

Profitability

This table compares IRIDEX and Presbia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IRIDEX	-6.23%	N/A	-11.16%
Presbia	N/A	N/A	N/A

Valuation and Earnings

This table compares IRIDEX and Presbia”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IRIDEX	$52.67 million	0.27	-$4.44 million	($0.19)	-4.34
Presbia	N/A	N/A	N/A	N/A	N/A

Presbia has lower revenue, but higher earnings than IRIDEX.

Risk and Volatility

IRIDEX has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Presbia has a beta of 5.91, meaning that its stock price is 491% more volatile than the S&P 500.

Summary

IRIDEX beats Presbia on 5 of the 9 factors compared between the two stocks.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

About Presbia

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.